At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 64 enrolled
Drug / intervention
TAK-491 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label and Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Phase 1 Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in Healthy Chinese Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-491 and TAK-491 placebo for Healthy Volunteer. Completed, enrolled 64 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the pharmacokinetics and safety of single- and multiple-dose of TAK-491 in healthy Chinese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartNov 2015
Primary CompletionMar 2017
TodayJul 2026
First PostedSep 4, 2015
Enrollment StartNov 20, 2015
Primary CompletionMar 17, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.8 years ago
Interventions
TAK-491drug
TAK-491 tablets
TAK-491 placebodrug
TAK-491 placebo-matching tablets